Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs.

BACKGROUND Since methamphetamine and other amphetamine-type stimulants (meth/amphetamine) can damage dopaminergic neurons, researchers have long speculated that these drugs may predispose users to develop Parkinson's disease (PD), a dopamine deficiency neurological disorder. METHODS We employed a retrospective population-based cohort study using all linked statewide California inpatient hospital episodes and death records from January 1, 1990 through December 31, 2005. Patients at least 30 years of age were followed for up to 16 years. Competing risks analysis was used to determine whether the meth/amphetamine cohort had elevated risk of developing PD (ICD-9 332.0; ICD-10 G20) in comparison to a matched population-proxy appendicitis group and a matched cocaine drug control group. Individuals admitted to hospital with meth/amphetamine-related conditions (n=40,472; ICD-9 codes 304.4, 305.7, 969.7, E854.2) were matched on age, race, sex, date of index admission, and patterns of hospital admission with patients with appendicitis conditions (n=207,831; ICD-9 codes 540-542) and also individuals with cocaine-use disorders (n=35,335; ICD-9 codes 304.2, 305.6, 968.5). RESULTS The meth/amphetamine cohort showed increased risk of PD compared to both that of the matched appendicitis group [hazard ratio (HR)=1.76, 95% CI: 1.12-2.75, p=0.017] and the matched cocaine group [HR=2.44, 95% CI: 1.32-4.41, p=0.004]. The cocaine group did not show elevated hazard of PD compared to the matched appendicitis group [HR=1.04, 95% CI: 0.56-1.93, p=0.80]. CONCLUSION These data provide evidence that meth/amphetamine users have above-normal risk for developing PD.

[1]  Peter C Austin,et al.  A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin use , 2006, Statistics in medicine.

[2]  Michael P Caligiuri,et al.  Do Preclinical Findings of Methamphetamine-Induced Motor Abnormalities Translate to an Observable Clinical Phenotype? , 2005, Neuropsychopharmacology.

[3]  L. Seiden,et al.  Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. , 1976, Drug and alcohol dependence.

[4]  Jason Fine,et al.  Competing Risks Regression for Stratified Data , 2011, Biometrics.

[5]  L. Seiden,et al.  Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers , 1984, Brain Research.

[6]  S. Kish,et al.  The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat , 1996, The Journal of Neuroscience.

[7]  Lon-Mu Liu,et al.  Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. , 2003, Addiction.

[8]  S. Sauerland,et al.  Laparoscopic versus open surgery for suspected appendicitis. , 2002, The Cochrane database of systematic reviews.

[9]  S. Kish,et al.  Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders , 2010, Movement disorders : official journal of the Movement Disorder Society.

[10]  W. Hall,et al.  Mortality among cocaine users: a systematic review of cohort studies. , 2011, Drug and alcohol dependence.

[11]  A. Hofman,et al.  Smoking and Parkinson's disease: Systematic review of prospective studies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[12]  R. Holloway,et al.  Accuracy of medicare claims data in identifying Parkinsonism cases: Comparison with the medicare current beneficiary survey , 2007, Movement disorders : official journal of the Movement Disorder Society.

[13]  J. Gracies,et al.  Movement disorders and AIDS: a review. , 2004, Parkinsonism & related disorders.

[14]  A. Levey,et al.  Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users , 1996, Annals of neurology.

[15]  Alan A. Wilson,et al.  Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker? , 2008, The Journal of Neuroscience.

[16]  A. Levey,et al.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users , 1996, Nature Medicine.

[17]  W. Hall,et al.  Mortality among amphetamine users: a systematic review of cohort studies. , 2009, Drug and alcohol dependence.

[18]  H. Fibiger,et al.  Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla. , 1971, European journal of pharmacology.

[19]  D. Wong,et al.  Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428 , 1998, The Journal of Neuroscience.

[20]  F. Rivara,et al.  Environmental factors and the risk for childhood pedestrian-motor vehicle collision occurrence. , 1990, American journal of epidemiology.

[21]  S. Ross,et al.  Inhibition of 3H-dopamine accumulation in reserpinized and normal rat striatum. , 2009, Acta pharmacologica et toxicologica.

[22]  R. Callaghan,et al.  The incidence of cardiovascular morbidity among patients with bipolar disorder: a population-based longitudinal study in Ontario, Canada. , 2010, Journal of affective disorders.

[23]  E. Cheng,et al.  Optimizing algorithms to identify Parkinson's disease cases within an administrative database , 2009, Movement disorders : official journal of the Movement Disorder Society.

[24]  P. Groves,et al.  Cocaine, in contrast to D-amphetamine, does not cause axonal terminal degeneration in neostriatum and agranular frontal cortex of Long-Evans rats. , 1988, Life sciences.

[25]  T. George,et al.  Co-morbidity of smoking in patients with psychiatric and substance use disorders. , 2005, The American journal on addictions.

[26]  Melania Pintilie,et al.  Competing Risks: A Practical Perspective , 2006 .

[27]  Peter C Austin,et al.  A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003 , 2008, Statistics in medicine.

[28]  M. Sofuoglu,et al.  The Impact of Cigarette Smoking on Stimulant Addiction , 2009, The American journal of drug and alcohol abuse.

[29]  P. Groves,et al.  Histological and ultrastructural evidence thatd-amphetamine causes degeneration in neostriatum and frontal cortex of rats , 1990, Brain Research.

[30]  S. Ettner,et al.  Linking hospital discharge and death records--accuracy and sources of bias. , 2004, Journal of clinical epidemiology.

[31]  D. Mash,et al.  Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims , 1997, Brain Research.

[32]  Vitaly Volberg,et al.  Decreased brain dopamine cell numbers in human cocaine users , 2009, Psychiatry Research.

[33]  Herng‐Ching Lin,et al.  An increased risk of stroke among young schizophrenia patients , 2008, Schizophrenia Research.

[34]  T. Guilarte.  Is methamphetamine abuse a risk factor in parkinsonism? , 2001, Neurotoxicology.

[35]  Herng‐Ching Lin,et al.  No Higher Risk of Myocardial Infarction Among Bipolar Patients in a 6-Year Follow-Up of Acute Mood Episodes , 2008, Psychosomatic medicine.

[36]  K. Marder,et al.  Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.

[37]  Stephen J. Kish,et al.  Pharmacologic mechanisms of crystal meth , 2008, Canadian Medical Association Journal.

[38]  D. Twelves,et al.  Systematic review of incidence studies of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[39]  V. Suppiramaniam,et al.  Methamphetamine-induced neurotoxicity: the road to Parkinson’s disease , 2009, Pharmacological reports : PR.

[40]  R. Hubbard,et al.  Is an internal comparison better than using national data when estimating mortality in longitudinal studies? , 2006, Journal of Epidemiology and Community Health.

[41]  Peter C Austin,et al.  Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations , 2009, Biometrical journal. Biometrische Zeitschrift.

[42]  C. Naylor,et al.  Burden of parkinsonism: A population‐based study , 2003, Movement disorders : official journal of the Movement Disorder Society.